CorMedix Inc. (CRMD) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, CorMedix reported revenue of $311.7M, up 617.0% from $43.5M the year before. Net income was $163.1M (a 52.3% net margin), or $2.04 per diluted share. Gross margin was 88.5% and operating margin was 48.2%. Operating activities generated $175.0M of cash, leaving $172.8M of free cash flow. At fiscal year end, CorMedix held $826.1M in total assets against $420.8M in total liabilities, including $144.8M of cash and equivalents.
Open the full interactive CorMedix financials → Quarterly statements, key ratios, valuation history and price charts.
CorMedix Key Stats
| Share Price | $7.39 |
|---|---|
| Market Cap | $683.4M |
| P/E Ratio | 3.6 |
| Revenue YoY Growth | +617.0% |
| 52-Week Range | $6.25 – $12.73 |
| Shares Outstanding | 78.4 million (basic, 2026 Q2) |
CorMedix Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $239,231 | $190,936 | $65,408 | — | $43.5M | $311.7M |
| Gross Profit | $34,385 | $41,998 | $61,674 | — | $40.3M | $275.7M |
| Operating Income | -$27.2M | -$29.4M | -$30.6M | -$49.0M | -$22.4M | $150.1M |
| Pre-Tax Income | -$27.2M | -$29.5M | -$30.3M | -$46.3M | -$19.3M | $150.0M |
| Income Tax | -$5.2M | -$1.3M | -$585,617 | — | -$1.4M | -$13.0M |
| Net Income | -$22.0M | -$28.2M | -$29.7M | -$46.3M | -$17.9M | $163.1M |
| Diluted EPS | -$0.77 | -$0.75 | -$0.74 | -$0.91 | -$0.30 | $2.04 |
CorMedix Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $104.3M | $128.6M | $127.4M | $101.9M |
| Net Income | $108.6M | $14.0M | $38.6M | $26.0M |
| Diluted EPS | $1.26 | $0.17 | $0.43 | $0.29 |
CorMedix Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $41.9M | $53.3M | $43.1M | $43.6M | $40.7M | $144.8M |
| Current Assets | $48.2M | $66.5M | $59.6M | $79.5M | $114.6M | $367.1M |
| Total Assets | $49.3M | $68.9M | $62.0M | $82.1M | $118.8M | $826.1M |
| Current Liabilities | $4.2M | $5.3M | $6.3M | $11.4M | $33.8M | $174.3M |
| Total Long-Term Debt | — | — | — | — | — | $294,626 |
| Total Liabilities | $5.1M | $6.1M | $7.0M | $11.9M | $34.2M | $420.8M |
| Shareholders' Equity | $44.2M | $62.8M | $55.1M | $70.1M | $84.7M | $405.3M |
CorMedix Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$22.0M | -$21.2M | -$24.4M | -$38.4M | -$50.6M | $175.0M |
| Cash From Investing | $7.4M | -$9.1M | -$3.7M | -$17.1M | $21.2M | -$308.4M |
| Cash From Financing | $40.1M | $41.8M | $17.9M | $55.9M | $26.3M | $238.5M |
| Free Cash Flow | -$22.1M | -$22.6M | -$24.6M | -$38.7M | -$50.7M | $172.8M |
Figures from CorMedix's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full CorMedix financials page for every line item.
CorMedix Company Profile
| Ticker | CRMD |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Parsippany, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer |
| SEC CIK | 0001410098 |
Frequently Asked Questions
What was CorMedix's revenue in fiscal 2025?
CorMedix (CRMD) reported revenue of $311.7M for fiscal 2025.
What is CorMedix's annual revenue history?
CorMedix's annual revenue by fiscal year: 2020: $239,231; 2021: $190,936; 2022: $65,408; 2024: $43.5M; 2025: $311.7M.
What was CorMedix's net income in fiscal 2025?
CorMedix reported net income of $163.1M for fiscal 2025.
What was CorMedix's earnings per share (EPS) in fiscal 2025?
CorMedix's diluted EPS was $2.04 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did CorMedix generate in fiscal 2025?
CorMedix generated $172.8M of free cash flow in fiscal 2025.
What was CorMedix's revenue last quarter?
In its most recent reported quarter (2026 Q2), CorMedix reported revenue of $101.9M.
How much debt does CorMedix have?
CorMedix reported $294,626 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of CorMedix are outstanding?
CorMedix reported a weighted average of 78.4 million basic shares outstanding in 2026 Q2.
What is CorMedix's market cap?
Based on its latest closing price, CorMedix (CRMD) has a market capitalization of about $683.4M.
When does CorMedix's fiscal year end?
CorMedix's fiscal year end, as registered with the SEC, is December 31.
Where is CorMedix headquartered?
CorMedix lists its business address in Parsippany, New Jersey in its SEC filings.